3.93MMarket Cap-209P/E (TTM)
3.3000High3.0801Low17.69KVolume3.1112Open3.1800Pre Close55.92KTurnover1.73%Turnover RatioLossP/E (Static)1.27MShares17.400052wk High0.22P/B3.18MFloat Cap2.920052wk Low--Dividend TTM1.02MShs Float170.0000Historical High--Div YieldTTM6.92%Amplitude2.9200Historical Low3.1600Avg Price1Lot Size
Pasithea Therapeutics Stock Forum
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
54 seconds ago, 4:02 AM PST
Via GlobeNewswire
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule --
-- No dose-limiting toxicities (DLTs) observed to date --
-- No rash observed to date --
📊⚡️📊
Pasithea Therapeutics Announces $5 Million Private Placement Priced at-the-Market Under Nasdaq Rules
No comment yet